Acasti Pharma Inc. (ACST)
Acasti Pharma Statistics
Share Statistics
Acasti Pharma has 10.14M shares outstanding. The number of shares has increased by 7.88% in one year.
| Shares Outstanding | 10.14M |
| Shares Change (YoY) | 7.88% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 4.65M |
| Failed to Deliver (FTD) Shares | 5.55K |
| FTD / Avg. Volume | 16.7% |
Short Selling Information
The latest short interest is 154.19K, so 1.52% of the outstanding shares have been sold short.
| Short Interest | 154.19K |
| Short % of Shares Out | 1.52% |
| Short % of Float | 1.93% |
| Short Ratio (days to cover) | 7.75 |
Valuation Ratios
The PE ratio is -2.56 and the forward PE ratio is null. Acasti Pharma's PEG ratio is 0.03.
| PE Ratio | -2.56 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.53 |
| P/FCF Ratio | -2.66 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Acasti Pharma has an Enterprise Value (EV) of 9.87M.
| EV / Sales | 0 |
| EV / EBITDA | -0.87 |
| EV / EBIT | -0.8 |
| EV / FCF | -0.8 |
Financial Position
The company has a current ratio of 14.26, with a Debt / Equity ratio of 0.
| Current Ratio | 14.26 |
| Quick Ratio | 14.26 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | -12.42 |
Financial Efficiency
Return on Equity is -20.82% and Return on Invested Capital is -16.1%.
| Return on Equity | -20.82% |
| Return on Assets | -17.53% |
| Return on Invested Capital | -16.1% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-401.66K |
| Employee Count | 32 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.78M |
| Effective Tax Rate | 12.15% |
Stock Price Statistics
The stock price has increased by 16.21% in the last 52 weeks. The beta is 1.52, so Acasti Pharma's price volatility has been higher than the market average.
| Beta | 1.52 |
| 52-Week Price Change | 16.21% |
| 50-Day Moving Average | 3.11 |
| 200-Day Moving Average | 2.99 |
| Relative Strength Index (RSI) | 54.72 |
| Average Volume (20 Days) | 33.25K |
Income Statement
| Revenue | n/a |
| Gross Profit | -11K |
| Operating Income | -11.31M |
| Net Income | -12.85M |
| EBITDA | -11.3M |
| EBIT | -17.68M |
| Earnings Per Share (EPS) | -1.35 |
Balance Sheet
The company has 23M in cash and 0 in debt, giving a net cash position of 23M.
| Cash & Cash Equivalents | 23M |
| Total Debt | 0 |
| Net Cash | 23M |
| Retained Earnings | -211.12M |
| Total Assets | 69.72M |
| Working Capital | 17.83M |
Cash Flow
In the last 12 months, operating cash flow was -12.33M and capital expenditures -22K, giving a free cash flow of -12.36M.
| Operating Cash Flow | -12.33M |
| Capital Expenditures | -22K |
| Free Cash Flow | -12.36M |
| FCF Per Share | -1.3 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ACST does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -39.1% |
| FCF Yield | -37.58% |
Analyst Forecast
The average price target for ACST is $10, which is 196.7% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10 |
| Price Target Difference | 196.7% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jul 10, 2023. It was a backward split with a ratio of 1:6.
| Last Split Date | Jul 10, 2023 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | -2.64 |
| Piotroski F-Score | 2 |